Huang Z X, Guo X Q, Deng W M, Zheng S L, Guo X, Huang Y K, Li T W
Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou 510317, China.
Zhonghua Yi Xue Za Zhi. 2018 Apr 17;98(15):1158-1161. doi: 10.3760/cma.j.issn.0376-2491.2018.15.007.
To assess the efficacy of Yisaipu tapering in patients with ankylosing spondylitis (AS). A total of 87 cases of AS patients from Guangdong Second Provincial General Hospital who were treated with Yisaipu and celecoxib were retrospectively analyzed from February 2013 to April 2017.All patients received full dose Yisaipu and celecoxib in the initial 12 weeks.After that, the patients in the full dose group maintained Yisaipu (50 mg/w) treatment from the 13(rd) to 24(th) week, while tapering group received Yisaipu 50 mg subcutaneous injection once every other week.By using AS disease activity score (ASDAS), Bath AS functional index (BASFI) and magnetic resonance (MR) score of sacroiliac joint (SIJ) plus recording adverse events, differences of efficacy and safety between groups were compared. ASDAS and BASFI of tapering group were 1.1±0.7 and 1.3±1.1, while those of full dose group were 1.0±0.7 and 1.1±1.0, respectively.No significant difference of ASDAS or BASFI was found between groups.Besides, the MR scores of tapering and full dose groups were 8±7 and 8±6 respectively before therapy, while they were significantly lower in the 24(th) week (4±4 and 4±3, <0.05). However, changes of MR score between groups were similar (>0.05). Dose tapering of Yisaipu subcutaneous injection might be effective for keeping stable of disease activity and function in patients with AS.Its efficacy is similar to those of full dose Yisaipu.
评估依赛普减量疗法对强直性脊柱炎（AS）患者的疗效。回顾性分析2013年2月至2017年4月在广东省第二人民医院接受依赛普和塞来昔布治疗的87例AS患者。所有患者在最初12周接受依赛普和塞来昔布的全剂量治疗。此后，全剂量组患者在第13至24周维持依赛普（50mg/周）治疗，而减量组每隔一周皮下注射一次50mg依赛普。通过使用AS疾病活动评分（ASDAS）、巴斯强直性脊柱炎功能指数（BASFI）以及骶髂关节（SIJ）的磁共振（MR）评分并记录不良事件，比较两组之间疗效和安全性的差异。减量组的ASDAS和BASFI分别为1.1±0.7和1.3±1.1，而全剂量组分别为1.0±0.7和1.1±1.0。两组之间ASDAS或BASFI无显著差异。此外，减量组和全剂量组治疗前的MR评分分别为8±7和8±6，而在第24周时显著降低（4±4和4±3，<0.05）。然而，两组之间MR评分的变化相似（>0.05）。皮下注射依赛普减量疗法可能对维持AS患者疾病活动度和功能稳定有效。其疗效与依赛普全剂量疗法相似。
